Navigation Links
Cancer cell 'bodyguard' turned into killer
Date:11/25/2008

id the research Kolluri and his team did "will cause a lot of attention in the cancer field."

"These investigators have done a nice job of combining findings of a basic nature as well as the preliminary studies needed to move to a preclinical evaluation. It's unusual for one single paper to make such a large step forward," he said.

Now one of the next steps, Melner said, is for researchers to determine what types of cancer and what stages of the disease this deadly Bcl-2 converter would combat.

Linda Wolff, a leukemia researcher at the National Institutes of Health's Center for Cancer Research in Bethesda, Md., said the researchers' discovery is "rare" in the world of cancer research. She added that it's important for two reasons.

"First, it may lead to a therapy that could potentially be used against many types of cancer," she said. "The reason for that is because it targets Bcl-2, and Bcl-2 is expressed in many types of cancers. So it could be useful in breast cancer and other carcinomas and leukemia, for example.

"The second reason it's important is that although the peptide they studied causes cancer cells to die, its effect on normal cells seems to be quite minimal," Wolff said. "A big problem in cancer research has been getting therapies that don't kill normal cells."

Dr. David Hockenbery, a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle, Wash., said that this new way of altering a protein so it injures a cell rather than merely disables it "is very unusual." He added that this finding would spur researchers to develop drugs or stable peptides that act on Bcl-2 at the Nur77 binding site.

"Quite conceivably, individual cancers may respond better to one type of Bcl-2 inhibitor than another," he said. "In the future, the availability of several targeting approaches against Bcl-2 should be useful in personalized cancer therapies."


'/>"/>

Contact: Siva Kolluri
siva.kolluri@oregonstate.edu
541-737-2940
Oregon State University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Biologists have learned where and how some plant seeds store ... iron content of plants. Their research helps address the worldwide ... team found that iron is stored in the developing vascular ... in research. In particular, iron is stored in the vacuole, ...
... Genomic technologies may have the potential to alleviate ... Researchers believe that biotechnology has the potential to ... crucially, resistance to insects and disease. This could ... both human and animal consumption. Researchers are ...
... team at the Consejo Superior de Investigaciones Científicas (CSIC) ... proteins in plant cells, a discovery that will enable ... these can be used to produce oral vaccines which, ... diseases. Moreover, this discovery opens the door to the ...
Cached Biology News:Plant studies reveal how, where seeds store iron 2Are genomic technologies the answer to world hunger? 2Vaccine-producing 'plant-factories' 2
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... A new infographic compiles useful information about Research ... learn how Apple’s new framework can change the way ... since Apple made Research Kit available to ... for developing medical research apps that Apple announced on ... collect secure clinical data and communicate via subjects’ smartphones. ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... , , , For automated purification of genomic and mitochondrial , DNA from ... Format: , 96-well plates (for ... QIAamp DNA Blood MDX Protocol, , , ... blood (with common anticoagulants , such as citrate and EDTA) , ...
... , , , , , For , HotStarTaq DNA Polymerase , ... , , , ... Storage and Stability , Technical Assistance , ... , , , ...
... , , , , Andreas Pahl, ... Department of Pharmacology, University of Erlangen, Erlangen, Germany , ... , , , , Drug library screening ... of RNA purification , and sensitive, quantitative, real-time RT-PCR analysis. This ...
Cached Biology Technology:QIAamp DNA Blood BioRobot MDx Kit 2HotStarTaq PCR Handbook 2HotStarTaq PCR Handbook 3HotStarTaq PCR Handbook 4HotStarTaq PCR Handbook 5HotStarTaq PCR Handbook 6HotStarTaq PCR Handbook 7HotStarTaq PCR Handbook 8HotStarTaq PCR Handbook 9HotStarTaq PCR Handbook 10HotStarTaq PCR Handbook 11HotStarTaq PCR Handbook 12HotStarTaq PCR Handbook 13HotStarTaq PCR Handbook 14HotStarTaq PCR Handbook 15HotStarTaq PCR Handbook 16HotStarTaq PCR Handbook 17HotStarTaq PCR Handbook 18HotStarTaq PCR Handbook 19HotStarTaq PCR Handbook 20HotStarTaq PCR Handbook 21HotStarTaq PCR Handbook 22HotStarTaq PCR Handbook 23HotStarTaq PCR Handbook 24HotStarTaq PCR Handbook 25HotStarTaq PCR Handbook 26HotStarTaq PCR Handbook 27HotStarTaq PCR Handbook 28HotStarTaq PCR Handbook 29HotStarTaq PCR Handbook 30HotStarTaq PCR Handbook 31HotStarTaq PCR Handbook 32HotStarTaq PCR Handbook 33High-throughput gene expression analysis to screen for anti-asthma drugs 2High-throughput gene expression analysis to screen for anti-asthma drugs 3